GT3-Nano based radioprotector drug promotes rapid recovery from 153Sm-EDTMP induced myelotoxcity

Conclusion: GT3-Nano is an effective radioprotectant drug for reducing myelotoxicity caused by 153Sm-EDTMP treatment at 40 times the usual human dose by weight in a mouse model. The result implies that using GT3-Nano we can aggressively treat patients with 153Sm-EDTMP while minimizing myelotoxicity.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Lee, S. G., Kalidindi, T. M., Punzalan, B., Pillarsetty, N., Larson, S. Tags: Basic Oncology & amp; Translational II Source Type: research